{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380004231521214978.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Shinya Sato"}],"foaf:familyName":[{"@value":"Sato"}],"foaf:givenName":[{"@value":"Shinya"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360004231521215104","@type":"Article","resourceType":"学術雑誌論文(journal article)","productIdentifier":[{"@type":"DOI","@value":"10.1007/s12185-018-2509-0"},{"@type":"URI","@value":"https://link.springer.com/article/10.1007/s12185-018-2509-0/fulltext.html"},{"@type":"URI","@value":"https://link.springer.com/content/pdf/10.1007/s12185-018-2509-0.pdf"},{"@type":"PMID","@value":"30032392"},{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2019223397"}],"notation":[{"@value":"Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s12185-018-2509-0_X8znl9ACTFRAlruIx3PTW71wXoK"},{"@type":"OPENAIRE","@value":"doi_dedup___::ecaefa620af62436af8ebd9f397b730c_X8znl9ACTFRAlruIx3PTW71wXoK"}]}